Signal-transducing adaptor protein (STAP)-2 is a recently identified adaptor protein that contains Pleckstrin homology (PH) and Src homology 2 (SH2)-like domains, and is also known to be a substrate of breast tumor kinase (Brk). In a previous study, we found that STAP-2 upregulated Brk-mediated activation of signal transducer and activator of 3
Introduction
A key step in the progression of the majority of breast cancers is the transition to steroid hormone-independent proliferation, and estrogen-independent tumors often have increased levels of total tyrosine kinase activity in both the cytosolic and membrane fractions. (1) Although breast tumor kinase (Brk), also known as protein tyrosine kinase 6, is undetectable in the normal mammary gland, it is overexpressed in more than 60% of human breast tumors and breast cancer cell lines, with the highest levels in advanced tumors. (2) (3) (4) Notably, small-interfering RNA (siRNA)-mediated downregulation of Brk expression in breast cancer cells results in a decrease in their growth capacity, (4) indicating that Brk is one of the major molecules causing excessive proliferation of breast cancer cells. Brk is a nonreceptor tyrosine kinase that activates signal transducer and activator of transcription (STAT) 3 and STAT5. (5, 6) Brk phosphorylates STAT3 and STAT5, leading to increases in their transcriptional activity. Furthermore, both STATs play fundamental roles in the normal growth and development of the mammary gland, (7) and are often overexpressed or constitutively activated in breast cancer tumors. (8) Thus, both the Brk/STAT3 and Brk/STAT5 axes are likely to be potential targets for breast cancer therapy.
On the other hand, signal-transducing adaptor protein (STAP)-2, which we isolated as a c-fms-interacting protein, is another substrate whose tyrosine residues are phosphorylated by Brk. (9) (10) (11) STAP-2 shows high sequence and structural similarities to STAP-1, which we cloned as a c-kit-interacting protein. (12) Both STAP-1 and STAP-2 contain an N-terminal Pleckstrin homology (PH) domain and a region weakly related to a Src homology 2 (SH2) domain (overall amino acid identity, 33%). The N-terminal PH domains of STAP-2 and STAP-1 share 36% identity and 58% similarity. The central region of STAP-2 is distantly related to the SH2 domain. This region of STAP-2 shares 40% sequence identity with that of STAP-1 and 29% sequence identity with the SH2 domain of human phospholipase C-γ2. However, STAP-2 has a C-terminal proline-rich region and a YXXQ motif, both of which are absent from STAP-1. Although STAP-1
shows a restricted expression pattern in hematopoietic cells, (12) STAP-2 is expressed in a variety of tissues and cells, such as lymphocytes, macrophages and hepatocytes, (10) and its abundant expression pattern suggests that STAP-2 influences a variety of signaling or transcriptional molecules. Indeed, we previously reported that STAP-2 can modulate the transcriptional activity of STAT3 and STAT5, as well as FcεRI-and Toll-like receptor-mediated signals. (10, (13) (14) (15) It is noteworthy that thymocytes and peripheral T cells from STAP-2-deficient mice show enhanced IL-2-or TCR-dependent cell growth and enhanced integrin-mediated adherence to fibronectin. (13, 16) In contrast, the roles of STAP-1 have not been identified.
Recently, we reported essential roles of STAP-2 in Brk-mediated STAT3 activation. (11, 17) In the absence of STAP-2, Brk failed to phosphorylate STAT3 in breast cancer cell lines. (17) With regard to Brk-mediated STAT5 activation, the involvement of STAP-2 in this process has not yet been clarified. However, the PH-and SH2-like domains of STAP-2 can recognize the C-terminal region of STAT5. (13) Thus, the ability of STAP-2 to interact with both Brk and STAT5 seems to suggest its possible roles in the Brk/STAT5 axis.
In this study, we focused on STAP-2 as a novel transcriptional regulator of STAT5 and demonstrated a functional link between STAP-2 and Brk/STAT5-mediated transcriptional activation and cell growth in human breast cancer cells.
Materials and methods
Reagents and antibodies. Expression vectors for STAP-2, STAT5a, STAT5b and STAT5-LUC were described previously. (13) anti-STAP-2 antibody was purchased from Everest Biotech (Oxfordshire, UK).
Cell culture, transfection, small interfering RNA (siRNA) and luciferase assays.
Human embryonic kidney carcinoma cell line, 293T, was maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS) and transfected by the standard calcium precipitation protocol. Luciferase assay was performed as described. (Fig. 3E) . Therefore, STAP-2 plays important roles in the Brk-mediated tyrosine-phosphorylation of STAT5 in breast cancer cells.
Functional role of the PH domain and Tyr250 of STAP-2 in Brk-mediated STAT5
activation. We previously reported that STAP-2 binds to several functional molecules.
For example, the SH2 domain of STAP-2 interacts with MyD88 and IKKs, (15) and the PH and SH2 domains of STAP-2 are responsible for the associations with STAT5, LMP1 and TRAF3. (13, 18) To assess the functional relationships among Brk, STAP-2 and STAT5, we determined the domains of STAP-2 responsible for Brk-mediated STAT5 activation. We transfected Brk, STAT5b and STAT5-LUC together with a series of STAP-2 deletion mutants ( 
Discussion
Several Brk-interacting proteins or Brk substrates, such as the RNA-binding protein Sam68 and the polypyrimidine tract-binding protein-associated splicing factor PSF, have been reported. (19, 20) However, the molecular mechanisms by which Brk cooperates with these proteins and participates in tumorigenesis remain poorly characterized. Our data will provide insights into the molecular mechanisms for how Brk acts as a tumorigenic protein in breast cancers.
STAT5 has two isoforms, STAT5a and STAT5b, which are encoded by two genes that are closely linked on human chromosome 17. (21) STAT5a and STAT5b share 96% sequence similarity in humans. STAT5a was originally identified as a mammary gland factor that augments milk protein expression, whereas STAT5b was shown to mediate the biological effects of growth hormone in the mammary gland. STAT5 is also activated in the downstream of other cytokines including erythropoietin, IL-2 or IL-3.
Although STAP-2 augmented Brk-mediated STAT5 activation in breast cancer cells, it has been shown to negatively regulate STAT5 activation in erythropoietin-, IL-2-and IL-3-induced signaling. (13) At the present time, we cannot explain these different effects of STAP-2 on STAT5 activation, although it is possible that unknown signal-specific or cell type-specific factors may influence the effects of STAP-2. Importantly, both STAT5a and STAT5b are overexpressed or constitutively activated in cancers, including some breast cancer tumors. (8, 22) However, recent evidence indicates that STAT5b, but not STAT5a, has a proproliferative role in breast cancer, head and neck cancer, and prostate cancer. (6, (23) (24) (25) In conclusion, the activation of STAT5 by Brk is one of the critical events during the Knockdown of each protein was confirmed until 6 days after siRNA trasfection. 
